Product approvals, OTC labeling not covered by risk assessment bills in Congress.
This article was originally published in The Tan Sheet
Executive Summary
PRODUCT APPROVALS WOULD BE EXEMPT FROM COST/BENEFIT ANALYSES OF RISK under a substitute amendment to Title III of the "Job Creation and Wage Enhancement Act" (HR 9) offered by Reps. Michael Oxley (R-Ohio) and Michael Bilirakis (R-Fla.) during a House Commerce Committee markup Feb. 8. Oxley chairs the commerce & trade subcommittee while Bilirakis is chair of the health subcommittee.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning